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Abstract
Introduction: Interleukin-1β (IL-1β) and nerve growth factor (NGF) are key regulators in the pathogenesis of
inflammatory arthritis; specifically, IL-1β is involved in tissue degeneration and NGF is involved in joint pain.
However, the cellular and molecular interactions between IL-1β and NGF in articular cartilage are not known.
Cartilage stem/progenitor cells (CSPCs) have recently been identified in osteoarthritic (OA) cartilage on the basis of
their migratory properties. Here we hypothesize that IL-1β/NGF signaling is involved in OA cartilage degeneration
by targeting CSPCs.
Method: NGF and NGF receptor (NGFR: TrkA and p75NTR) expression in healthy and OA human articular cartilage
and isolated chondrocytes was determined by immunostaining, qRT-PCR, flow cytometry and western blot. Articular
cartilage derived stem/progenitor cells were collected and identified by stem/progenitor cell characteristics. 3D-cultured
CSPC pellets and cartilage explants were treated with NGF and NGF neutralizing antibody, and extracellular matrix
changes were examined by sulfated glycosaminoglycan (GAG) release and MMP expression and activity.
Results: Expression of NGF, TrkA and p75NTR was found to be elevated in human OA cartilage. Cellular changes upon
IL-1β and/or NGF treatment were then examined. NGF mRNA and NGFR proteins levels were upregulated in cultured
chondrocytes exposed to IL-1β. NGF was chemotactic for cells isolated from OA cartilage. Cells isolated on the basis of
their chemotactic migration towards NGF demonstrated stem/progenitor cell characteristics, including colony-forming
ability, multi-lineage differentiation potential, and stem cell surface markers. The effects of NGF perturbation in cartilage
explants and 3D-cultured CSPCs were next analyzed. NGF treatment resulted in extracellular matrix catabolism
indicated by increased sGAG release and MMP expression and activity; conversely, treatment with NGF neutralizing
antibody inhibited increased MMP levels, and enhanced tissue inhibitor of matrix metalloprotease-1 (TIMP1) expression
in OA cartilage explants. NGF blockade with neutralizing antibody also affected cartilage matrix remodeling in 3D-CSPC
pellet cultures.
Conclusion: Our results strongly suggest that NGF signaling is a contributing factor in articular cartilage degeneration
in OA, which likely targets a specific subpopulation of progenitor cells, the CSPCs, affecting their migratory and matrix
remodeling activities. These findings provide novel cellular/signaling therapeutic targets in osteoarthritic cartilage.
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Introduction
The degenerative joint disease osteoarthritis (OA) is a
major cause of mobility loss, and represents the most
prevalent form of musculoskeletal disease worldwide [1, 2].
The Centers for Disease Control and Prevention (CDC)
reports that 52.5 million US adults had arthritis in 2010–
2012, and estimated up to 67 million by the year 2030 [3].
Current clinical OA management is mainly concerned
with symptom reduction (e.g., pain, swelling, stiffness) [4],
with oral nonsteroidal anti-inflammatory drugs (NSAIDs)
being the most commonly used pharmacological treat-
ment at mid-stage of the disease, and arthroplasty, an
irreversible procedure, as the final solution to maintain
joint function. The pathogenesis of OA is incompletely
understood. Better understanding of the mechanisms of
OA progress is thus critical for development of an inter-
vention method.
The primary target tissue of OA is the articular cartil-
age, a physiologically nonself-renewing, avascular tissue
that functions as the load-bearing joint surface. Cartilage
tissue is composed of over 90 % extracellular matrix
(ECM) and less than 10 % chondrocytes in total volume.
Collagens and proteoglycans (PGs) present in the ECM
are the major macromolecules directly responsible for
the load-bearing properties of the hyaline articular cartil-
age [5]. Joint cartilage destruction is triggered by a num-
ber of events, including changes in the mechanical
environment, biochemical alterations of the ECM, and
biological responses of chondrocytes, the subchondral
bone, and the synovium to inflammation.
Proinflammatory cytokines, such as interleukin (IL)-1β,
are key regulators in the pathogenesis of inflammatory
arthritis, including tissue degeneration. IL-1β induces pro-
duction of major extracellular proteolytic enzymes in
chondrocytes, such as matrix metalloproteinases (MMPs)
and a disintegrin-like and metalloproteinase with throm-
bospondin motifs (ADAMTS) [6, 7]. Wheaton et al. [8]
reported that intraarticular injection of recombinant
porcine IL-1β into the pig knee joint resulted in cartilage
loss. Lai et al. [9] reported that induction of IL-1β in
healthy mouse joints could cause joint structure changes,
dysfunction, and pain. IL-1β could also lead chondrocytes
to express more proinflammatory cytokines such as tumor
necrosis factor alpha (TNFα), IL-8, complement factors,
and prostaglandin E2 [7, 10–12]. IL-1β is an important
therapeutic target of OA, and drugs that block IL-1β
action have been developed and in use for decades [10].
Nerve growth factor (NGF), an important signaling
molecule involved in joint pain, is a key regulator of
rheumatoid arthritis pathogenesis, and has recently been
implicated in OA pain. NGF and nerve growth factor
receptor (NGFR) may act in OA pain through at least
two mechanisms: increasing proliferation of sensory
neurons [13]; and changing the pain threshold through
high-affinity NGFR (TrkA)-mediated sensitization of
sensory neurons [14]. A recent clinical trial showed that
intravenous injection of the NGF neutralizing antibody,
Tenezumab® (Pfizer, New York, NY, USA) can relieve
OA joint pain [15]. These functional effects are likely to
occur within synovial tissue [16, 17] and osteochondral
junctions [18], as well as in dorsal root ganglia [19–21].
Interestingly, other research findings also suggest NGF
involvement in cytokine-mediated OA pathogenesis,
with articular cartilage as a target tissue. For example,
articular cartilage is immunopositive for NGF, and
higher expression of NGF and TrkA [22] is observed in
OA [23]. Furthermore, genome-wide association scan re-
sults revealed the association of an NGF variant,
MCF2L, with OA [24], suggesting that OA may be re-
lated to interruption of NGF functional balance. At
present, the role of NGF/NGFR in articular cartilage
biology and OA pathogenesis is unclear.
Cartilage stem/progenitor cells (CSPCs) have recently
been found within human articular cartilage [25–28].
These cells are thought to respond to injury and migrate
through the disease-affected tissue zones, and are
characterized as stem/progenitor cells in vitro by virtue
of their self-renewal ability, differentiation multipotency,
and stem cell markers [29, 30]. Expression of several
mesenchymal progenitor cell markers, including Stro-1,
VCAM (CD166), Notch-1, etc. [31], has been detected
in OA but not in normal human articular cartilage,
suggesting that OA may activate an endogenous CSPC
population within the tissue. The signaling events in car-
tilage degeneration are unclear. Recent studies showed
induction of CSPC homing by injured cartilage condi-
tioned medium, dead cell debris, and chromosomal pro-
teins [30], suggesting soluble cell recruitment signals.
Here we hypothesized that IL-1β/NGF signaling is in-
volved in OA cartilage degeneration by targeting CSPCs.
The hypothesis is tested by: characterizing NGF and
NGFR expression in OA cartilage; assessing the effect of
IL-1β treatment on NGF/NGFR in cartilage explants
and in cartilage-derived CSPCs; and examining the
effects of NGF perturbation on the cartilage-forming
activities of CSPCs in three-dimensional (3D) cultures.
Our findings strongly suggest coordinated signaling by
IL-1β and NGF in cartilage degeneration via CSPCs,
which represent a potential therapeutic target for OA.
Methods
Tissue harvest and explant culture
Cartilage explant cultures were taken from macros-
copically unaffected areas of the femoral condyle from
total knee arthroplasty (Institutional Review Board
approval, consent exempted: University of Pittsburgh,
PA, USA and University of Washington, Seattle, WA,
USA). Adult articular cartilage was obtained from nine
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females and six males (average age, 60.1 years). Histo-
logical slides of normal adult (n = 3) and fetal articular
cartilage (n = 3) were donated by the Department of
Pathology and Anatomy, Zhejiang University School of
Medicine, Zhejiang, China, and were examined by histo-
logical staining and immunohistochemistry.
To study the effects of NGF treatment on tissue morph-
ology, a white, smooth piece of articular cartilage (~1 cm×
1 cm and 3–5 mm in depth) harvested from a nonlesion
area of the joint surface was cut orthogonally into ~2 mm
sized pieces, and was cultured with varying concentrations
of NGF for up to 14 days. At the end of culture, the ex-
plants were fixed in 4 % paraformaldehyde and processed
for histology. Sections of 14 μm thickness were examined
histologically using Safranin-O/Fast Green staining.
To examine the effects of NGF treatment on cartilage
matrix degeneration, cartilage explants were cultured with
serum-free medium for 12 hours, and dispersed at the
same wet weight (0.5–1 g/well, depending on each donor)
into a multiwell (12-well or 24-well) plate. The same vol-
ume of culture medium with or without NGF and/or anti-
NGF antibody was added to each well (0.3 g wet weight
tissue/ml culture medium) and subsequently collected at
various time intervals up to 2 weeks to assay for release of
sulfated glycosaminoglycan (sGAG) and MMPs. The
freshly isolated tissue was denoted as the day 0 sample.
The culture medium consisted of Dulbecco’s Modified
Eagle’s medium (DMEM; Life Technologies, Thermo Fisher,
Grand Island, NY, USA), supplemented with ITS+ and 1 %
penicillin–streptomycin (Life Technologies), with 1 ml
medium for ~300 mg tissue. Treatments included 10 ng/ml
recombinant human NGF-β (Sigma, St. Louis, MO, USA),
and/or 10 ng/ml NGF neutralizing antibody (ab16161;
Abcam, Cambridge, MA, USA). Medium was removed and
collected every 2 days during the 2-week culture period.
Cell isolation, culture, and characterization
Primary human chondrocytes from distal femoral con-
dyles were isolated by enzymatic digestion. Briefly, the
tissue was minced into ~1 mm3 pieces and digested for
6 hours at 37 °C with a 0.2 % solution of collagenase type
I (Life Technologies). Cells were transferred to monolayer
culture in DMEM/Ham’s F12 Medium (1:1; Life Tech-
nologies), supplemented with 10 % fetal bovine serum
(FBS) and penicillin/streptomycin, and cultured under
standard conditions. For the NGF release test, early-
passage (before passage 2) chondrocytes were cultured as
a high-density monolayer (>95 % confluence) and treated
with 100 pg/ml IL-1β for 1 week. The medium was chan-
ged on days 1, 4, and 7 and collected for NGF enzyme-
linked immunosorbent assay (ELISA; R&D Systems,
Minneapolis, MN, USA). RNA was isolated on day 7.
Based on the migratory ability of CSPCs, we collected
the NGF responsive CSPCs from a Transwell system
(see Cell migration assay). The NGF-attracted cells were
trypsinized from the bottom of the Transwell insert and
cultured in growth medium. Stem cell characteristics
were tested as described in the following by flow cyto-
metric analysis, and on the basis of multilineage differ-
entiation and colony-forming ability. To test the effects
of NGF on CSPCs, migratory cells were cultured as a
high-density monolayer (>95 % confluence). After treat-
ment in serum-free medium for 12 hours, cells were
treated with 10 ng/ml NGF or 100 pg/ml IL-1β for
48 hours and RNA was extracted for quantitative RT-PCR
analysis of gene expression.
To investigate the effect of NGF on cell prolifera-
tion, cells were seeded in 96-well plates at a density
of 3000 cells/cm2 in a medium containing 2 % FBS. After
attachment, cells were treated with 10 or 100 ng/ml NGF,
10 ng/ml NGF neutralizing antibody, or the combination
of 10 ng/ml NGF and antibody for 1, 3, 5, and 7 days. Cell
proliferation was tested using the CCK-8 Kit (DOJINDO,
Rockville, MD, USA).
Immunostaining
For immunostaining, tissue specimens were fixed in 4 %
paraformaldehyde and processed as cryosections, while
cells were transferred to 24-well plates and cultured for
16 hours, after which they were fixed with 4 % para-
formaldehyde. The samples were incubated with mouse
monoclonal antibodies (human CD271; BD Pharmingen,
San Diego, CA, USA), followed by fluorescein isothiocyan-
ate (FITC)-conjugated, secondary rabbit anti-mouse IgG
(Life Technologies). Cell nuclei were counterstained with
4′,6-diamidino-2-phenylindole (DAPI), or with a Histostain
Kit according to the manufacturer’s protocol (Life Tech-
nologies). Immunostained sections and cells were examined
by phase-contrast and epifluorescence microscopy using an
Olympus i X71 microscope (Olympus, Tokyo, Japan).
Flow cytometric analysis
Antibodies (from Pharmingen/BD Biosciences, San Diego,
CA, USA; unless specified otherwise) used for flow cytome-
try included: FITC-conjugated specific antibodies to human
CD34 (clone 581, IgG1,κ), CD90 (clone 5E10, IgG1,κ),
CD45 (clone 30-F11, IgG2a,κ; eBioscience, San Diego,
CA, USA); phycoerythrin (PE)-conjugated mouse-
specific antibody to human CD44 (clone 515, IgG1,κ);
and nonconjugated mouse-specific antibody to human
CD105 and CD271, detected with FITC-conjugated
rabbit anti-mouse IgG (Life Technologies). PE-
conjugated or FITC-conjugated isotype-matched IgGs
were used as controls. Cells (5 × 105 cells/ml) were
incubated with primary antibodies for 30 minutes at
4 °C. After washing, the cells were fixed with 1 % parafor-
maldehyde and analyzed using a Beckman-Coulter FC 500
MCL/MPL flow cytometer (Brea, CA, USA).
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Cell migration assay
The migratory activity of chondrocytes isolated from
healthy and OA articular cartilage at different passages was
assessed as follows. Fifty thousand cells were seeded in the
upper insert of a Transwell plate (Costar 3422, Corning,
NY, USA) and cultured in serum-free DMEM. Serum-free
medium, containing NGF (10 ng/ml) and/or NGF neutral-
izing antibody (10 ng/ml), was added to the lower chamber.
After 24-hour incubation, the inserts were removed and
the upper surface of the filter was scraped free of cells and
debris. After staining with DAPI, the number of migrated
cells detected on the underside of the Transwell filter was
counted in five randomly selected fields (100× magnifica-
tion), and the results per microscopic field are expressed as
mean ± standard deviation (SD). Data presented are repre-
sentative of three independent experiments.
Multilineage differentiation potential
The differentiation potential of CSPCs was tested on the
basis of induced osteogenesis, adipogenesis, and chondro-
genesis. For osteogenesis, cells were plated at low density
(1 × 103 cells/cm2) in a 24-well plate and cultured with
10 mM β-glycerolphosphate (Sigma), 0.1 μM dexametha-
sone (Sigma), and 50 μg/ml ascorbate (Sigma) in DMEM–
high glucose medium containing 10 % FBS and 1 % peni-
cillin–streptomycin for 2 weeks. Osteogenesis was assessed
by alkaline phosphatase (ALP) histochemical staining
(ALP kit; Beyotime Biotechnology, Shanghai, China). For
adipogenesis, confluence cultures were treated with 1 mM
dexamethasone, 10 μg/ml insulin, and 0.5 mM isobutyl-
xanthine (all Sigma) in DMEM–high glucose medium
containing 10 % FBS and 1 % penicillin–streptomycin for
2 weeks. Intracellular accumulation of lipid droplets was
detected by Oil Red O (Sigma) staining. For chondrogene-
sis, high-density pellets of 2 × 105 cells were formed by
centrifugation in U-shaped bottom 96-well plates and
cultured in 10 ng/ml TGF-β3 (PeproTech, Rocky Hill, NJ,
USA), 50 μg/ml ascorbic acid (Sigma), 40 μg/ml proline,
and 0.1 μM dexamethasone in DMEM–high glucose
medium containing ITS and 1 % penicillin–streptomycin.
The medium was changed every 2–3 days, and cell pellets
were observed at intervals of 14 and 21 days. To examine
the influence of NGF, some pellets were treated with
10 ng/ml human recombinant NGF-β, 10 ng/ml NGF neu-
tralizing antibody, or 10 ng/ml NGF neutralizing antibody
matched isotype (mouse IgG1, monoclonal isotype control,
ab81032; Abcam) during the entire 2-week culture period.
Matrix sGAG in the pellets was histologically stained with
Safranin O, and chondrogenesis was analyzed according to
a previously published histological pellet scoring system
[32]. sGAG content was quantified using the Blyscan assay
and normalized to double-stranded DNA content (Pico-
green; Life Technologies). Gene expression in the pellets
was evaluated by quantitative RT-PCR (see later).
Data were obtained from three independent experi-
ments, with each experiment using pooled CSPCs from
four or five different donors (n = 12).
RNA extraction and quantitative RT-PCR
RNA was isolated using the RNeasy Mini Kit (QIAGEN,
Valencia, CA, USA) according to the manufacturer’s in-
structions. Quantitative RT-PCR was performed using
SYBR Green PCR Master Mix (Life Technologies) with a
StepOne Plus Realtime PCR system (Applied Biosystems,
Thermo Fisher, Grand Island, NY, USA). The PCR cycling
consisted of 45 cycles of amplification of the template
DNA with primer annealing at 60 °C. The relative level of
gene expression was calculated using the 2-delta delta Ct
method. 18S rRNA, RPL13a, and GAPDH were chosen as
housekeeping genes, which in general yielded similar re-
sults. The primer sequences used in this study are listed in
supplementary materials (Additional file 1: Table S1).
Zymography
Zymography was performed in 10 % gelatin polyacryl-
amide gel (Novex; Life Technologies). Medium samples
(10 μl each) were mixed with zymogram sample buffer
(BioRad, Hercules, CA, USA) and subjected to SDS-
PAGE. The gels were then equilibrated with renaturation
buffer (BioRad) and incubated with development buffer
(BioRad) overnight at 37 °C. Bands were visualized by
staining gels with Simply Blue Safe Stain (Invitrogen,
Themo Fisher, Grand Island, NY, USA). At least two
replicates were carried out for each sample analyzed by
zymography. The MMP2 and MMP9 bands were
digitally imaged and semiquantified by Image J 1.45s (NIH,
Bethesda, MD, USA).
MMP activity assay
5-FAM-Pro-Cha-Gly-Nva-His-Ala-Dap(QXL™520)-NH2
(Anaspec, Fremont, CA, USA), the fluorogenic MMP sub-
strate XI [33, 34], was added into medium samples at a
final concentration of 8.33 ng/μl. Fluorescence measure-
ments (Ex/Em= 485/520 nm) were taken every 5 minutes
for 1 hour in a microplate reader to determine substrate
cleavage kinetics. Enzyme activities based on reaction rates
were normalized to the original tissue wet weight.
ELISA
Medium samples from IL-1β-treated chondrocytes were
collected as already described. Chondrocytes from five
patients were pooled for the test, and NGF concentra-
tions (pg/ml) in the medium samples were determined
using a commercially available ELISA kit (R&D Systems).
All assays were carried out in triplicate. Total amounts
of NGF released (pg) were calculated and normalized to
double-stranded DNA content (mg), and values are
shown as mean ± standard error (SE).
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Immunoblotting
Proteins were extracted using RIPA buffer (Sigma) and
protease inhibitor cocktail (Sigma), boiled in sample
buffer (BioRad), and separated by SDS-PAGE using 6 %
stacking gel and 12 % separating gel (cell sample: 50 μg/
lane; medium sample: 20 μl/lane). PVDF (0.45 μm;
Millipore, Billerica, MA, USA) blots were prepared and
incubated at 4 °C overnight with the primary antibodies
(1:1000; anti-MMP3, Abcam; anti-TIMP1, R&D; anti-
GAPDH, Abcam), followed by enzyme-conjugated sec-
ondary antibodies (GE, Marlborough, MA, USA), and
detection was carried out with the ECL Kit (Pierce,
Thermo Fisher, Grand Island, NY, USA) and visualized
using a FOTO/Analyst1 Fx CCD imaging system (Foto-
dyne, Hartland, WI, USA). Images were analyzed by NIH
Image J 1.45s. Each blot was repeated at least in duplicate,
and representative scans are presented.
Statistical analysis
Analysis of results from at least three independent experi-
ments was performed using SPSS 16.0 software(SPSS Inc.
Chicago, IL, USA). Results are reported as mean ± SD, un-
less specified otherwise. Student’s t test was performed be-
tween two groups. For experiments with more than two
groups and multiple time points, after testing for normal
distribution and variance homogeneity, a two-way/split plot
analysis of variance (ANOVA) and post-hoc pairwise com-
parison of mean values were carried out. Statistical signifi-
cance was considered at p <0.05.
Results
NGFRs are expressed in OA cartilage
Expression of the high-affinity NGFR, TrkA, was re-
ported in adult articular cartilage, and reported to be
higher in OA cartilage [23]. We examined the expression
pattern of both TrkA and the low-affinity NGFR,
p75NTR (also known as the stem cell marker CD271),
in human knee articular cartilage sections by immuno-
histochemistry. CD271 staining was negative in fetal and
normal adult human cartilage, but positive in the
superficial zone of early OA articular cartilage (Fig. 1a).
(Note: CD271/p75NTR-positive cells were seen in
normal rabbit articular cartilage, suggesting species
difference (see Additional file 1: Figure S1).) As OA
progressed, cells were strongly positive for CD271 and
TrkA appeared in all zones in late OA articular cartil-
age (Fig. 1a, b). The presence of both NGF and its
high/low-affinity receptors in OA cartilage suggests
that NGF signaling activity may be involved in OA
pathogenesis.
IL-1β regulates NGF/NGFR expression in chondrocytes
We observed that NGF and its receptors, TrkA and
p75NTR, were expressed in human articular cartilage-
derived chondrocytes and their levels were regulated by
the OA mediator, IL-1β. After culturing in 100 pg/ml
IL-1β (level similar to that found in human OA synovial
fluid) [35, 36], chondrocytes isolated from macros-
copically asymptomatic articular cartilage in total knee
Fig. 1 Immunodetection of NGF receptors in OA articular cartilage. a Immunostaining of the NGF low-affinity receptor, CD271 (or p75NTR), in fetal
(n = 3, biological replicates), healthy (normal, n = 3, biological replicates), and OA (early and late stage, n = 5 each, biological replicates) hyaline
cartilage from human femoral condyles, showing the superficial zone, middle zone, and deep zone. b Immunostaining of the NGF high-affinity
receptor, TrkA, in OA (late stage) hyaline cartilage from human femoral condyles, showing the superficial zone, middle zone, and deep zone.
CD271/p75NTR and TrkA presence is revealed by DAB staining (brown). n= 3–5 biological replicates. Negative control, without the use of primary antibody,
is at the bottom-left. Bar = 100 μm. Arrows, positive signals of DAB staining. OA osteoarthritis, p75NTR low-affinity NGFR, TrkA high-affinity NGFR
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arthroplasty samples showed higher levels of NGF gene
expression (Fig. 2a). Higher levels of NGF protein were
also detected by ELISA in the culture medium of IL-1β-
treated cells (Fig. 2b), suggesting that NGF expression
could be one of the cellular responses of chondrocytes
to the proinflammatory effects of IL-1β.
Both NGFRs, the high-affinity NGFR, TrkA, and the
low-affinity NGFR, p75NTR, were detected in cultured
chondrocytes by immunoblotting (Fig. 2c), suggesting
that chondrocytes have the potential to respond to NGF.
In addition, the level of p75NTR was increased in the
IL-1β treatment chondrocytes.
CSPCs migrate towards NGF
The surface marker CD271 was present at abundant
levels in late OA cartilage. Late OA cartilage-derived pri-
mary cells were therefore used to examine the effects of
NGF treatment. Upon treatment with 10 ng NGF/ml for
24 hours, we observed a change in the morphology of
CD271+ cells from a well-spread shape to a more com-
pact phenotype with defined cell borders (Fig. 3a).
As migratory activity is characteristic of CSPCs [29, 30],
we analyzed cell migration in a Transwell setup. NGF
recruited more cells migrating through the membrane
than culture medium alone (Fig. 3b). Specifically, this
promigration effect was inhibited by the addition of NGF
neutralizing antibody. To confirm the CSPC characteris-
tics of the migratory cells, cells collected from the bottom
of the insert in the Transwell setup (Fig. 3c) were analyzed
for their colony-formation ability, differentiation multipo-
tency (Fig. 3d), and the presence of mesenchymal stem
cell (MSC) -associated surface markers (see Additional
file 1: Figure S2). These cells showed a colony-forming
efficiency of 38.6 ± 14.8 % at passage 4; they also positively
responded to osteogenic, adipogenic, and chondrogenic
induction (Fig. 3d). Flow cytometry showed that these
cells were positive for MSC surface markers CD90, CD73,
CD105, CD166, CD44, and CD29, and negative for the
hematopoietic stem cell markers CD34 and CD45, indicat-
ing a similar epitope profile between these cells and adult
MSCs (see Additional file 1: Figure S2).
CSPCs lost the CD271+ phenotype during in vitro culture
The surface marker CD271 remained present (34 %
positive) in primary cells isolated from late OA cartilage,
and then rapidly disappeared after their culture passa-
ging, as demonstrated by immunofluorescence and flow
cytometry analyses (Fig. 4a). NGF treatment was not
able to recover the CD271+ phenotype in cells that had
been cultured in monolayer for three passages (Fig. 4b).
Interestingly, healthy cartilage-derived primary chondro-
cytes or late passage OA-derived chondrocytes lost their
chemotaxis towards NGF (Fig. 4c).
The effects of NGF on CSPCs were further examined
to exclude the possibility that NGF and NGF neu-
tralizing antibody increased cell numbers to cause false
positives in the Transwell test. Unlike the effect observed
on cell migration (Fig. 3b), neither treatment with NGF
(10 and 100 ng/ml) nor with NGF antibody (10 ng/ml)
affected cell proliferation (Fig. 4d).
We further tested the effects of NGF and IL-1β on the
in vitro cultured CSPCs. No changes were seen in the
expression levels of the cartilage matrix genes, COL2
and AGN, and the OA-associated matrix degeneration
genes, MMP2/3/13 and ADAMTS-4/5, under NGF treat-
ment, but treatment with IL-1β significantly increased
Fig. 2 IL-1β stimulation of NGF/NGFR expression and release in human chondrocytes. Adult human chondrocytes in culture were treated with
100 pg/ml IL-1β in growth medium (GM) consisting of DMEM with 10 % FBS. a Higher NGF gene expression in response to treatment with IL-1β
(GM versus GM+ IL-1β; *p <0.05), analyzed by real-time RT-PCR on day 7 of treatment, with RPL13a as housekeeping gene control. b Higher NGF
secretion in culture medium in response to IL-1β treatment (GM versus NGF; *p <0.05), measured by ELISA and expressed relative to double-stranded
DNA content. c Higher NGFR expression in human chondrocytes in response to IL-1β analyzed by western blotting. Ten biological cell donors were
analyzed. Experiments were carried out with three technical replicates using three pooled batches of samples, with each batch consisting of five
randomly chosen samples. Images were digitally scanned and values are normalized to GAPDH and day 0 GM group, and expressed as mean ± SE.
Representative images from one batch experiment are shown. GAPDH protein loading control, IL interleukin, NGF nerve growth factor, p75NTR low-affinity
NGFR, TrkA high-affinity NGFR
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MMPs (Fig. 4e). Thus, NGF did not appear to act on
chondrocytes in a manner similar to the more generic
proinflammatory cytokines, such as IL-1β [37–40].
To further study the influence of NGF in OA cartilage,
it is necessary to maintain the NGFR+ phenotype of
CSPCs. OA cartilage explants were therefore used as a
model to study influences on tissue degeneration.
NGF exposure increases matrix degradation in OA human
cartilage explants
To investigate the effects of NGF on OA cartilage,
human cartilage tissue explants were harvested from
early OA joints and cultured in serum-free medium con-
taining 10 ng/ml NGF for 14 days. The culture medium
was collected at 24 hours after treatment, and every
48 hours thereafter. Histological examination of tissue
sections with Safranin O staining (Fig. 5a) and colori-
metric quantitation of sGAG content in the culture
medium (Fig. 5b) showed that NGF treatment increased
sGAG loss and release from cartilage explants.
Because of their known involvement in cartilage
matrix degradation, production of MMPs in the cultured
explants was analyzed. NGF treatment resulted in higher
MMP levels in OA cartilage explants (Fig. 5e). Specific-
ally, we analyzed the explant culture medium for MMP2
and MMP9 activity by means of zymography (Fig. 5c).
MMP9 activity was turned on rapidly by NGF on day 1
(Fig. 5c), and remained elevated for the remainder of the
Fig. 3 Response of CSPCs to NGF. a Change in morphology of CD271+ cells upon NGF treatment (10 ng/ml, 24 hours): CD271 (green), nuclei
(blue). Bar = 50 μm. b Cells isolated from late OA articular cartilage are chemotactic for NGF (10 ng/ml). p <0.05, *versus control group, #versus
NGF + ab group (n = 3, mean ± SD). c Schematic chart of isolation NGF chemotactic cells with Transwell. d Characteristics of NGF chemotactic
cells: clonogenicity and differentiation multipotency. bar = 2 cm; osteogenesis, alkaline phosphatase (ALP), bar = 2 mm; adipogenesis, lipid droplet,
Oil-red O; bar = 50 μm; chondrogenesis of pellet culture, GAG staining with Safranin O, bar = 500 μm. ab NGF neutralizing antibody, CFU crystal
violet, NGF nerve growth factor, OA osteoarthritis
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culture period. Likewise, MMP2 activity was significantly
increased upon NGF treatment (p = 0.038, n = 5) (Fig. 5c).
Immunoblotting results also showed that more MMP3
was released into the culture medium from the NGF-
treated explants (p = 0.040, n = 3) (Fig. 5d). Interestingly,
NGF treatment appeared to increase matrix degener-
ation only in OA cartilage tissue; in isolated CSPCs, no
changes were seen in the expression levels of cartilage
matrix genes and OA-associated matrix degeneration
genes (Fig. 4e).
To further assess the potential effects of NGF signaling
in matrix metabolism, OA cartilage explants were
treated with 10 ng/ml NGF and/or NGF neutralizing
antibody (Fig. 5e). We observed that perturbing NGF
signaling by adding NGF or NGF neutralizing antibody
affected matrix degeneration. NGF increased MMP
activity, and NGF antibody treatment blocked MMP
activity (Fig. 5e). Interestingly, NGF signaling also affected
the level of tissue inhibitor of matrix metalloprotease-1
(TIMP-1) in OA cartilage. NGF treatment reduced TIMP-1
on day 1, while the addition of NGF antibody increased
TIMP-1 release on days 5–7 (Fig. 5f).
Taken together, these results strongly suggest that
NGF plays a role in cartilage degeneration. It is possible
that IL-1β activates the NGF/NGFR(s), and OA cartilage
responds to NGF via CSPCs. That CSPCs are activated
via IL-1β/NGF signaling represents a potentially new cell
target in OA pathogenesis.
NGF effects on CSPC matrix production and remodeling
To investigate the functional role of NGF in cartilage
matrix remodeling, OA cartilage-derived CSPCs were
Fig. 4 CD271+ cartilage-derived cells: loss of CD271+ phenotype and response to NGF during in vitro culture. a Abundance of CD271+ cells in the
cartilage-derived cells determined by flow cytometry. Passages in culture: P0, 33.60 ± 5.09 %; P1, 3.00 ± 2.33 %; P3 and P5, signal undetectable (P0 versus
P1: *p <0.05; n = 5, biological replicates; mean ± SD). b CD271+ cells (%) at P3, after treatment with 10 ng/ml NGF for 24 hours. Representative sample is
shown (n= 3). c Early-passage cells isolated from healthy cartilage (passage 1 (P1); n= 3, biological replicates, mean ± SD) and late passage from OA
articular cartilage (passage 4 (P4); n= 5, biological replicates, mean ± SD) are not chemotactic for NGF (10 ng/ml), p >0.05. d CSPC proliferation (n = 4).
e Gene expression profiles of COL2, AGN, MMP2/3/13, and ADAMTS-4/5, in CSPCs before and after NGF (10 ng/ml, 48 hours) and IL-1β (100 pg/ml,
48 hours) treatment. IL-1β versus control: *p <0.05, n = 5, biological replicates, mean ± SD, values normalized to RPL13a. ab NGF neutralizing antibody,
ADAMTS a disintegrin-like and metalloproteinase with thrombospondin motifs, IL interleukin, MMP matrix metalloproteinase, NGF nerve growth factor,
OA osteoarthritis
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cultured as 3D pellets in chondrogenic medium and
treated with NGF in combination with the NGF neutral-
izing antibody. The cultured cell pellets were harvested
on day 14 and evaluated histologically by Safranin O
staining, and scored on the basis of staining intensity,
cell-to-cell distance, and cell morphology, according to a
pellet scoring system [32] (Fig. 6a). With NGF and NGF
blocking antibody treatment for a time span from day 7
to day 14, the matrix genes, COL1A1, COL2A1, AGN,
and SOX9, did not significantly change at day 14 (Fig. 6c),
and the histological pattern also did not change in the
CSPC pellets. However, treatment with NGF or with
Fig. 5 NGF treatment results in matrix degeneration in OA cartilage. Cartilage explants from OA tissue were cultured in serum-free medium (control),
or treated with NGF for 14 days, and then the explants and culture medium were analyzed separately. a Safranin O staining of cartilage explants
isolated from a uniform region before and after 14 days of culture, with or without 10 ng/ml NGF. b Medium sGAG release, normalized to tissue wet
weight (mg) (n = 4, biological replicates). Representative samples are presented: values are mean ± SE; NGF versus control, two-way ANOVA, p <0.0001).
c MMP zymography analysis of medium MMP2 and MMP9 activity (n = 5; representative images shown). Zymography analysis of MMP2 release in
medium at day 1 (n = 5 biological replicates; *p <0.05), semiquantified based on band intensity signal. d Western blot analysis of medium MMP3
release during culture; semiquantified based on band intensity (n = 3 biological replicates; values are mean ± SD; NGF versus control, two-way ANOVA,
p <0.005; blots from same patient sample). e Medium MMP activity. Medium samples from day 1, days 5–7, and days 11–13 were assayed (n = 4,
biological replicates; NGF versus control group, and NGF versus NGF + ab group at day 13; *p <0.05, values are mean ± SD). f Western blot analysis
of medium TIMP1 release at days 1, 7, and 13 (n = 4, biological replicates; representative results shown). ab NGF neutralizing antibody (10 ng/ml),
MMP matrix metalloproteinase, NGF nerve growth factor, sGAG sulfated glycosaminoglycan, TIMP1 tissue inhibitor of matrix metalloprotease-1
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NGF antibody alone reduced sGAG accumulation in the
pellets (Fig. 6b). Perturbing NGF signaling by treatment
with NGF or NGF neutralizing antibody therefore did
not inhibit matrix production, but there appeared to be
reduced matrix accumulation.
Discussion
Increased IL-1β and NGF levels in the synovial fluid are
symptoms of arthritis [23, 41]. It is well recognized that IL-
1β is involved in cartilage degeneration and NGF mediates
neuropathic pain in the disease state of OA [14], but the
role of NGF in cartilage degeneration is unclear. In the
present study, we have explored the role of IL-1β/NGF sig-
naling in OA articular cartilage. Expression of NGF and
NGFR was elevated in healthy human chondrocytes, in re-
sponse to the proinflammatory OA inducer, IL-1β (Fig. 2).
NGF treatment increased OA cartilage matrix degradation
(Fig. 5), with NGF/NGFR action targeting CSPCs, illustrated
by NGF induction of chemotactic CSPC migration (Fig. 3).
Our findings also showed that NGF signaling affected cartil-
age tissue integrity and related cell activities (Fig. 5), as well
as matrix accumulation in chondrogenic cultures of CSPCs
(Fig. 6). Taken together, these findings strongly suggest the
functional involvement of IL-1β/NGF signaling in OA
pathogenesis, acting through CSPCs (Fig. 7).
CSPCs were initially found and associated with tissue
injury [30] or degenerative and inflammatory conditions
as in OA, and migratory activity has been recognized as
a characteristic behavior of CSPCs [29, 30]. We found
here that cells isolated from late OA cartilage are chemo-
tactic for NGF. Interestingly, the low-affinity NGFR, also
known as CD271, an early stem cell marker, is highly
expressed in late OA cartilage (Fig. 1). We also observed
that only cells from late OA articular cartilage, but not
cells from normal cartilage, are chemotactic for NGF
(Fig. 4c). We therefore speculate that CD271+ cells are the
NGF responsive CSPCs in OA cartilage. We found that
the CD271+ cells are unable to maintain their phenotype
after isolation and passage in vitro (Fig. 4a). Interestingly,
we also observed species variation, as rabbit articular car-
tilage displays a different distribution of CD271+ cells,
compared with human (see Additional file 1: Figure S1).
Further studies in human and other appropriate animal
models are needed and under development to verify that
the CD271+ cells represent the sole or primary NGF
chemotactic migratory cell subpopulation.
We observed that IL-1β acts upstream of NGF in
OA-related NGF/NGFR signaling (Fig. 2). Specifically,
treatment of chondrocytes with IL-1β increases NGF
mRNA and protein levels, and both high-affinity and
low-affinity NGFRs—TrkA [22] and p75NTR/CD271,
respectively—are positively immunostained in OA
articular cartilage [23]. Therefore, IL-1β could be in-
volved in the activation of the NGF responsive cells in
healthy cartilage (Fig. 7). We also found that NGF/
NGFR is involved in OA cartilage degeneration, as NGF
treatment increases matrix degradation in OA cartilage
explants, indicated by increased GAG release and MMP
Fig. 6 NGF signaling is partially involved in matrix remodeling in chondrogenic CSPCs. High-density pellets were formed using 2 × 105 CSPCs,
cultured in chondrogenesis medium (CM) for the first week, and then treated with 10 ng/ml NGF, NGF and NGF neutralizing antibody (NGF + ab),
10 ng/ml NGF neutralizing antibody (ab), or 10 ng/ml NGF neutralizing antibody matched IgG1 (isotype). Pooled CSPCs were used for the pellet study,
derived from 14 patients and randomly distributed in five independent trials. Representative data presented are from five technical replicates for each
group. a Safranin O staining of CSPC pellets at day 14. Bar = 100 μm. b sGAG quantification in pellets, normalized to double-stranded DNA. *p <0.05,
versus CM group, values are mean ± SD. c Gene expression of COL1A1, COL2A1, AGN, and SOX9 in CSPC pellets analyzed by quantitative RT-PCR, with
RPL13a as housekeeping gene. Values are mean ± SD. NGF nerve growth factor, sGAG sulfated glycosaminoglycan
Jiang et al. Arthritis Research & Therapy  (2015) 17:327 Page 10 of 13
activity, particularly MMP2, MMP3, and MMP9. Taken
together, these findings strongly support the functional
involvement of IL-1β/NGF signaling in the pathogenesis
of OA. However, it is still unclear whether the CSPCs
are quiescent stem/progenitor cells that are activated by
IL-1β, or whether the healthy chondrocytes after
treatment with IL-1β convert to NGF responsive cells.
Additional study is clearly needed.
Clinical studies with NGF neutralizing antibody have
demonstrated its beneficial effects in reducing pain
levels in the treatment of OA [15]. In animal studies,
blocking NGF and NGFR-mediated signaling through
the use of neutralizing antibody to NGF [19] or to the
NGFR, TrkA [20, 42], could reduce OA pain [20, 21];
however, the effect on joint cartilage health is unknown.
We therefore examined the effects of inhibition of NGF
on the biological activities of articular cartilage and
cartilage-derived cells. We observed that NGF-mediated
CSPC migration is blocked by treatment with NGF
neutralizing antibody (Fig. 3b). In addition, MMP
activity is also partially suppressed by treatment with
NGF neutralizing antibody in cultured cartilage explants
(Fig. 5e). These results suggest that blocking NGF may
affect joint cartilage via cell-mediated mechanism, in
addition to the reported pain relief [15]. Interestingly,
the NGF effect on MMPs is only observed in OA cartil-
age explants, but not in the cultured chondrocytes (e.g.,
lack of stimulation of MMP13 and ADAMTS-5 shown
in Fig. 4e), suggesting the importance of the diseased
tissue environment. Previous study of relevance is an
animal experiment showing that NGF-induced weight-
bearing asymmetry in non-OA rats was normalized to
that of saline-injected controls by 1 week after NGF
antibody injection, whereas pain behavior remained
augmented in NGF-injected OA rats [21]. Taken
together, these findings strongly suggest that while NGF
may not be the initiator of OA, it is likely to contribute
to OA pathogenesis, not only via neuropathic pain but
also via pathological changes in cartilage structure by
targeting the CSPCs [43].
To examine the functional role of NGF signaling in
CSPCs, we applied an in vitro 3D, chondrogenic CSPC
pellet culture model. Our results showed that perturbing
NGF signaling with NGF (10 ng/ml) and NGF neutraliz-
ing antibody resulted in less cartilage ECM accumulation
(Fig. 6b). However, the general histological structure and
expression of matrix genes was not affected (Fig. 6c).
These findings suggest that NGF may partially function
in modulating the CSPC matrix assembly process. It is
interesting that NGF neutralizing antibody alone lowers
matrix accumulation, suggesting possible biological ac-
tivity of the endogenous traces amount of NGF (~pg/μg
double-stranded DNA, see Fig. 2b). Further study is
therefore needed to clarify this role.
We also tested whether blocking NGF may affect other
activities of joint cartilage in addition to the reported
pain relief [15]. Interestingly, treatment with NGF neu-
tralizing antibody reduced MMP activity and maintained
TIMP1 production in OA cartilage explants (Fig. 5f ),
suggesting the possibility that blockade of NGF could
reduce matrix loss in OA cartilage. Because of the spe-
cies variation of NGFR distribution (Additional file 1:
Figure S1) and the challenge in maintaining NGFR ex-
pression in vitro (Fig. 4), an appropriate animal model is
DEGENERATION 
+ 
Fig. 7 Schematic of NGF role and IL-1β involvement in OA. See text for details. IL interleukin, MMP matrix metalloproteinase, NGF nerve growth
factor, NGFR nerve growth factor receptor, OA osteoarthritis
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needed in the future to study the long-term in vivo
effects of the NGF signaling blockades.
Conclusions
The results reported here strongly suggest that NGF
signaling is a contributing factor in articular cartilage
degeneration in OA, which probably targets a specific
subpopulation of progenitor cells, the CSPCs. More in-
depth knowledge of the molecular and cellular mechan-
ism of IL-1β/NGF signaling will be crucial in exploring
its potential utility as a therapeutic target for OA.
Additional file
Additional file 1: Figure S1 showing immunodetection of CD271/
p75NTR in normal rabbit cartilage, Figure S2 showing characterization
of the cell surface epitope profile of migratory cells isolated from
human OA articular cartilage, Figure S3 showing the gene expression
profile of human OA cartilage explants after NGF (10 ng/ml)
treatment for 14 days, and Table S1 presenting primer sequences for
real-time RT-PCR. (DOCX 1277 kb)
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